Medical Treatment
Nephrology
New Drug (Nephoxil) focuing upon Hyperphosphatemia in Dialysis and Anemia in Chronical Kidney Disease.
| Product Name | Regions | Indications | Progress |
|---|---|---|---|
| Nephoxil | Taiwan | 1. Hyperphosphatemia | NDA Obtained |
| 2. Anemia | PIII Last Patient Out (H2 2022) | ||
| Auryxia | USA | 1. Hyperphosphatemia | NDA Obtained |
| 2. Anemia | sNDA Obtained | ||
| Riona | Japan | 1. Hyperphosphatemia | NDA Obtained |
| 2. Anemia | sNDA Obtained | ||
| Nephoxil | Korea | Hyperphosphatemia | NDA Obtained |
| (National Health Insurance Discussion) | |||
| Nephoxil | China | Hyperphosphatemia | NDA Submission (H2 2022) |
| Fexeric | EU | Hyperphosphatemia | Pending Akebia Authorization |
| Nephoxil | Thailand | Hyperphosphatemia | NDA Submission (Soon) |
| Nephoxil | Southeast Asia | Hyperphosphatemia | Authorization Negotiating (Ongoing) |
※ The above dates are subjected to changes, please refresh our website for continuous update.
